Which muscle relaxants are safe to use concurrently with lithium and vilazodone?

Muscle Relaxant Safety with Lithium and Vilazodone

Baclofen and tizanidine are the safest muscle relaxants to combine with lithium and vilazodone, with baclofen being the preferred first choice due to its lack of significant drug interactions with these medications.

Recommended Muscle Relaxants

First-Line Choice: Baclofen

• Baclofen is the safest option for concurrent use with lithium and vilazodone 1
• No documented interactions with either lithium or vilazodone
• Should be continued perioperatively without interruption 1
• Critical caveat: Never discontinue baclofen abruptly, especially if used long-term, as withdrawal can cause life-threatening complications including hallucinations, seizures, fever, and potentially rhabdomyolysis 1

Second-Line Choice: Tizanidine

• Tizanidine is generally safe with lithium and vilazodone, though requires more caution 1
• Important interaction with lithium: When prescribed with methadone (not applicable here), tizanidine increases QTc prolongation risk 2
• No direct documented interactions with vilazodone
• Must be tapered slowly if discontinuation is needed to avoid rebound hypertension and tachycardia 1
• Contraindicated with CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) 1

Muscle Relaxants to AVOID

Absolutely Contraindicated:

Carisoprodol, cyclobenzaprine, metaxalone, and methocarbamol should NOT be used with this medication combination 1, 3:

• Carisoprodol: High abuse potential, causes significant CNS depression, and has dangerous withdrawal syndrome 1, 4
• Cyclobenzaprine: Structurally related to tricyclic antidepressants with anticholinergic effects; can precipitate serotonin syndrome when combined with vilazodone 1
• Metaxalone and Methocarbamol: Increase sedation risk and have unclear mechanisms that may interact unpredictably 1, 3

Critical Drug Interaction Concerns:

Serotonin Syndrome Risk: Vilazodone is an SSRI with 5-HT1A partial agonist properties 5. The FDA label explicitly warns about serotonin syndrome when vilazodone is combined with other serotonergic drugs, specifically listing lithium as a high-risk combination 5. Adding muscle relaxants with serotonergic properties (like cyclobenzaprine) creates a dangerous three-way interaction.

CNS Depression: Guidelines strongly recommend against combining opioids with benzodiazepines and muscle relaxants/sedative-hypnotics due to respiratory depression risk 3. This same principle applies to combining multiple CNS depressants with lithium and vilazodone.

Clinical Algorithm for Selection

1. First, assess spasticity vs. muscle spasm:

   • For spasticity (upper motor neuron): Choose baclofen 1
   • For muscle spasm (musculoskeletal): Choose baclofen or tizanidine 1

2. Screen for contraindications:

   • If patient takes CYP1A2 inhibitors → Use baclofen only (tizanidine contraindicated) 1
   • If patient has hepatic/renal dysfunction → Use baclofen (tizanidine should be avoided) 1
   • If elderly patient → Prefer baclofen (tizanidine causes more hypotension/sedation) 1

3. Monitor for serotonin syndrome when initiating any muscle relaxant with this combination:

   • Agitation, confusion, tremor, hyperthermia, hyperreflexia, myoclonus 5
   • If symptoms develop, discontinue all serotonergic agents immediately

Important Safety Considerations

Lithium-Specific Concerns: While older research suggested lithium may enhance neuromuscular blockade with certain muscle relaxants (particularly suxamethonium, pancuronium, and vecuronium) 6, this primarily applies to surgical paralytic agents, not oral muscle relaxants. However, this underscores the need for caution with any neuromuscular-active drug.

Vilazodone-Specific Concerns: The FDA label emphasizes monitoring for bleeding risk when vilazodone is combined with other medications 5. While not directly related to muscle relaxants, this highlights the need for comprehensive medication review.

Long-term Use Caution: Evidence for long-term muscle relaxant use (>4-6 weeks) is limited, with most benefit seen in painful cramps, spasticity, and neck pain rather than chronic low back pain or fibromyalgia 7. Consider deprescribing if pain goals are not met within 4-6 weeks.